Thalidomide in Treating Patients With Myelofibrosis

Completed · Phase 2

Conditions studied: Primary Myelofibrosis

In brief

Phase II trial to study the effectiveness of thalidomide in treating patients who have myelofibrosis. Thalidomide may stop the growth of myelofibrosis by stopping blood flow to the cancer cells.

Key facts

Study ID

NCT00015821

Run by

National Cancer Institute (NCI)

People needed

43

Starts

2000-05-01

Last updated by the study team

2013-10-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed myelofibrosis with myeloid metaplasia
• Agnogenic myeloid metaplasia
• Post-polycythemic myeloid metaplasia
• Post-thrombocythemic myeloid metaplasia
• No metastatic carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease, acute leukemia (including M7), or acute myelofibrosis
• No chromosomal translocation t(9;22) or bcr/abl gene rearrangement
• Presence of reticulin fibrosis in bone marrow and leukoerythroblastosis and dacrocytosis in peripheral blood
• Presence of anemia (hemoglobin less than 10 g/dL), palpable splenomegaly, or hepatomegaly
• Performance status - ECOG 0-2
• Absolute neutrophil count greater than 750/mm\^3
• Platelet count less than 400,000/mm\^3
• WBC less than 50,000/mm\^3
• Bilirubin no greater than 2 mg/dL (if total bilirubin elevated, direct bilirubin must be normal)
• AST no greater than 3 times upper limit of normal (ULN)
• Alkaline phosphatase no greater than 3 times ULN
• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile women must use at least 1 highly active method AND 1 additional effective method of contraception for at least 4 weeks before study, during study, and for at least 4 weeks after study
• Fertile men must use effective contraception during study and for at least 4 weeks after study
• No uncontrolled infection
• No concurrent condition that would preclude study
• No peripheral neuropathy
• At least 1 month since prior interferon, pirfenidone, anagrelide, or epoetin alfa

Where it is running

• North Central Cancer Treatment Group — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.